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In multiple sclerosis (MS), Th17 cells are critical drivers of autoim-
mune central nervous system (CNS) inflammation and demyelin-
ation. Th17 cells exhibit functional heterogeneity fostering both
pathogenic and nonpathogenic, tissue-protective functions. Still,
the factors that control Th17 pathogenicity remain incompletely
defined. Here, using experimental autoimmune encephalomyelitis,
an established mouse MS model, we report that therapeutic ad-
ministration of activin-A ameliorates disease severity and alleviates
CNS immunopathology and demyelination, associated with decreased
activation of Th17 cells. In fact, activin-A signaling through activin-like
kinase-4 receptor represses pathogenic transcriptional programs in
Th17-polarized cells, while it enhances antiinflammatory gene mod-
ules. Whole-genome profiling and in vivo functional studies revealed
that activation of the ATP-depleting CD39 and CD73 ectonucleotidases
is essential for activin-A–induced suppression of the pathogenic
signature and the encephalitogenic functions of Th17 cells. Mech-
anistically, the aryl hydrocarbon receptor, along with STAT3 and
c-Maf, are recruited to promoter elements on Entpd1 and Nt5e
(encoding CD39 and CD73, respectively) and other antiinflamma-
tory genes, and control their expression in Th17 cells in response
to activin-A. Notably, we show that activin-A negatively regulates
the metabolic sensor, hypoxia-inducible factor-1α, and key inflam-
matory proteins linked to pathogenic Th17 cell states. Of trans-
lational relevance, we demonstrate that activin-A is induced in
the CNS of individuals with MS and restrains human Th17 cell re-
sponses. These findings uncover activin-A as a critical controller of
Th17 cell pathogenicity that can be targeted for the suppression of
autoimmune CNS inflammation.
cytokines | autoimmune neuroinflammation | Th17 cell differentiation |
ectonucleotidases | activin-A
Multiple sclerosis (MS) is a chronic inflammatory de-myelinating disease of the central nervous system (CNS)
that affects nearly 2.5 million people worldwide (1, 2). The
majority of MS patients manifest a relapsing-remitting form
(RRMS) that represents the second cause of disability in young
adults and is characterized by acute relapses and remissions of
neurological deficit (1, 2). Studies in experimental autoimmune
encephalomyelitis (EAE), a widely used mouse MS model, have
uncovered T helper-type (Th) 17 cells as key drivers of autoim-
mune neuroinflammation (2, 3). Of clinical relevance, increased
frequencies of Th17 cells are detected in the peripheral blood,
the cerebrospinal fluid, and the brain of RRMS patients, and in
individuals with secondary progressive MS (4–6). Importantly,
Th17-related molecules correlate with parameters of MS
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activity and relapse frequency (4–6). Hence, the development of
therapeutic strategies targeting pathogenic Th17 cell functions is
essential for the management of MS.
Accumulating evidence proposes that Th17 cell differentiation
and pathogenicity is controlled by specific cytokines and the CNS
microenvironment (2–9). For example, Th17 cells differentiated
in vitro with IL-6, IL-23, and IL-1β or TGF-β3 exhibit enhanced
pathogenic potential and induce autoimmune neuroinflammation
upon transfer in vivo (2–10). In contrast, TGF-β1 and IL-6 gen-
erate Th17 cells with limited pathogenic activity (2–10). Discrete
molecular programs distinguish pathogenic and nonpathogenic
Th17 subsets, with high IL-23R, IFN-γ, granulocyte macrophage-
colony stimulating factor (GM-CSF), and low CD5L expression
characterizing pathogenic cells and increased IL-10, CTLA-4, and
c-Maf levels associated with nonpathogenic cells (2–11). Similarly,
in humans, Th17 cells coproducing IL-17 and IFN-γ mirror
pathogenic Th17 cells, while those expressing IL-17 and IL-10
constitute nonpathogenic cells (12, 13). Elegant studies have
corroborated the heterogeneity and plasticity of Th17 cells,
demonstrating that Th17 cells, generated in vivo or in vitro under
noninflammatory conditions, exhibit increased IL-10 expression
and can transdifferentiate into T regulatory (Treg) type 1-like cells
(14, 15). Still, the precise factors and molecular pathways that
skew pathogenic Th17 cells, generated in the context of highly-
inflammatory conditions, such as those occurring during CNS
autoimmunity, into nonpathogenic cells remain elusive.
Activin-A is a pleiotropic cytokine that exerts crucial functions
in development, hematopoiesis, and stem cell maintenance (16,
17). Activin-A is expressed by the majority of innate and adaptive
immune cells and signals through two type I (activin receptor
type 1A [or activin receptor-like kinase-ALK2], and activin re-
ceptor type 1B [or ALK4]) and two type II (ActRIIA and
ActRIIB) receptors (18). Although activin-A and TGF-β belong
to the same superfamily, they exert distinct nonredundant, and
often opposing, functions associated with their different signal-
ing receptors and the unique repertoire of cell-extrinsic and
-intrinsic regulators (17). Activin-A exerts a broad spectrum of
pro- and antiinflammatory functions, depending on the type of
immune response and the spatiotemporal context (16, 17).
Seminal studies have reported instrumental roles of activin-A in
the differentiation of mouse Th9 and Foxp3+ Treg cells and
follicular Th cells in humans (19–21). Our previous studies have
demonstrated that activin-A mitigates Th2 cell-driven allergic
responses in experimental asthma and asthmatic individuals,
associated with the generation of IL-10–producing Treg cells (22,
23). Still, the effects of activin-A on key aspects of Th17 cell
responses, including differentiation and pathogenicity, and the
molecular mechanisms involved, remain unexplored.
Here, we report that in vivo administration of activin-A, in a
therapeutic regime, attenuates CNS inflammation and demyelin-
ation and ameliorates EAE severity. In fact, activin-A signaling
through its major type I receptor, ALK4, represses pathogenic
transcriptional programs in Th17 cells, while it boosts antiin-
flammatory gene modules. Whole-genome profiling and functional
studies revealed that the ectonucleotidases, CD39 and CD73, are
involved in activin-A–induced suppression of Th17 responses.
Mechanistic studies demonstrated that activin-A activates the tran-
scription factor (TF), aryl hydrocarbon receptor (AhR), which,
along with STAT3 and c-Maf, control CD39 and CD73 expression
in Th17 cells. Interestingly, activin-A also negatively regulates in-
flammatory proteins linked to pathogenic Th17 states, including
hypoxia-inducible factor-1α (Hif1-α). Overall, these studies uncover
activin-A as a therapeutic target that can be harnessed for the
control of Th17 cell-driven autoimmune neuroinflammation.
Results
Activin-A Is Increased in the CNS of Patients with RRMS. Initially, we
investigated the expression of activin-A in individuals with
RRMS under stable condition (SI Appendix, Table S1). Re-
markably, our findings demonstrated a marked up-regulation of
activin-A levels in the cerebrospinal fluid and the serum of
patients with RRMS as compared to controls, pointing to a role
of activin-A in the regulation of MS (Fig. 1A). Similarly, we
detected a substantial increase of activin-A in the spinal cord,
serum, and brain of mice undergoing EAE induced by immuni-
zation of C57BL/6 mice with myelin oligodendrocyte peptide
(MOG35–55) peptide emulsified in complete Freund’s adjuvant
(CFA) (SI Appendix, Fig. S1A).
In Vivo Administration of Activin-A Attenuates the Clinical Severity of
EAE. On the basis of these findings, we investigated the role of
activin-A in autoimmune CNS inflammation in vivo. For this, we
treated mice with activin-A systemically, every 3 d after EAE
onset, in a therapeutic setting. Notably, activin-A administration
attenuated EAE severity, as reflected by a significant reduction
in the loss of motor function and paralysis throughout the period
of clinical evaluation, while control (PBS)-treated mice de-
veloped a typical ascending disease (Fig. 1B). In support, histo-
pathological analyses revealed markedly reduced immune cell
infiltration and demyelination in the spinal cords (Fig. 1C). EAE
amelioration by activin-A was also associated with significantly
decreased frequencies of CNS-infiltrating CD45+CD11b+Ly6C+
inflammatory myeloid cells, as well as IL-17+, IFN-γ+, and IL-
17+IFN-γ+ CD4+ T cells (Fig. 1 D and E). In line with the
suppression of inflammatory cell infiltration, activin-A decreased
GM-CSF, TNF-α, and IL-1β production in the CNS (Fig. 1F). In
contrast, IL-10 levels were significantly increased in the spinal
cords upon therapeutic activin-A administration (Fig. 1F).
To explore the effects of activin-A on encephalitogenic T cell
responses, we analyzed the recall response to MOG35–55. Flow
cytometry analyses revealed that draining lymph node (DLN)
cells obtained from activin-A–treated mice at the peak of EAE,
contained significantly decreased frequencies of IL-17+, GM-
CSF+, IFN-γ+, and IL-17+IFN-γ+ CD4+ T cells upon restim-
ulation ex vivo (Fig. 1G and SI Appendix, Fig. S1B). In contrast,
we detected a nearly twofold increase in the percentages of IL-
10+ and Foxp3+ CD4+ T cells in mice administered with activin-
A, compared to PBS-treated controls (Fig. 1G and SI Appendix,
Fig. S1 B and C). In agreement with the flow cytometry data, IL-
17, GM-CSF, IFN-γ, and TNF-α release in DLN culture super-
natants was diminished, concomitant with a marked increase in
IL-10 production in mice treated with activin-A (Fig. 1H). Col-
lectively, these findings provide evidence that in vivo adminis-
tration of activin-A ameliorates the clinical severity of EAE
associated with decreased encephalitogenic T effector responses.
Activin-A Represses the Pathogenic Signature of Th17 Cells. Based on
the suppression of pathogenic Th17-linked effector responses
and EAE, we next investigated whether activin-A interferes with
Th17 cell differentiation. To investigate this, we polarized naive
CD4+ T cells under highly inflammatory Th17-skewing condi-
tions (IL-1β, IL-,6 and IL-23) in the presence of activin-A, and
analyzed their global gene-expression profile using RNA sequenc-
ing (RNA-seq). Differential expression analysis, summarized in an
MA plot and heatmap visualization, uncovered notable differences
in the transcriptome of act-A–Th17 cells, with 972 genes signifi-
cantly regulated (greater than twofold [log2(FC) < −1 or > 1]), 741
of which were up-regulated and 231 down-regulated, compared to
Th17 cells (Fig. 2A and SI Appendix, Fig. S2A). Interestingly, we
detected a marked down-regulation of genes related to the path-
ogenic Th17 signature, such as Tbx21 and Batf, whereas genes as-
sociated with nonpathogenic Th17 cells—including Ahr, Maf and
Ctla4—were enriched in act-A–Th17 cells (Fig. 2 A and B) (9–11,
24, 25). Ingenuity pathway analysis (IPA) and gene ontology (GO)
studies detected an enrichment of the “role of cytokines in medi-
ating communication between immune cells,” “immune cell traf-
ficking,” and “inflammatory and cell-mediated immune response”
among differentially expressed genes (DEGs) in act-A–Th17 cells
(Fig. 2C). Moreover, a dense network of molecular interactions
associated with AhR signaling, a TF known to affect T cell differ-
entiation (4), was enriched in act-A–Th17 cells (Fig. 2D).
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Fig. 1. In vivo administration of activin-A attenuates the clinical severity of EAE. (A) Activin-A expression in patients with RRMS (n = 11) and disease controls
(n = 20). Each symbol represents an individual donor. Statistical significance was obtained by the Mann–Whitney U test. CSF, cerebrospinal fluid. (B) Active
EAE was induced in C57BL/6 mice by subcutaneous immunization with MOG35–55 peptide in CFA and PTX injection. Activin-A or control (PBS) were admin-
istered (intraperitoneally) on disease onset (days 10 to 12) and every 3 d until killed. Clinical scores and regression analysis are depicted. Dashed lines indicate
the 95% confidence intervals of the regression lines. Statistical analysis was performed by two-way ANOVA, followed by Bonferroni’s multiple comparisons
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To validate the RNA-seq findings, we carried out qPCR
analyses. Indeed, Th17 cells differentiated in the presence of
activin-A exhibited decreased expression of Ifng, Csf2, Tbx21,
and Il1b, genes associated with pathogenic Th17 cell functions,
concomitant with enhanced Il10, Ahr, and Maf mRNA levels,
linked to nonpathogenic cells (Fig. 2E) (9, 13, 26). In support of
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the bioinformatics analyses, activin-A up-regulated by nearly
fourfold the expression of xenobiotic metabolizing enzyme cy-
tochrome P450 (encoded by Cyp1a1), a major AhR transcrip-
tional target (Fig. 2E) (21). Cytokine profiling also revealed that
activin-A decreased the release of proinflammatory IFN-γ, GM-
CSF, and TNF-α in culture supernatants, concomitant with
marked increase IL-10 production (Fig. 2F). In line with the
qPCR data, Foxp3 protein levels remained unaltered in act-
A–Th17 cells (SI Appendix, Fig. S2B). Il17 and Rorc levels
were not affected, suggesting that although activin-A decreases
expression of critical pathogenic genes, it maintains factors as-
sociated with the fundamental Th17 cell program (Fig. 2 E
and F) (8–11, 24, 25). To further validate the suppressive
effects of activin-A on the pathogenic Th17 profile, we utilized
Il17aCreR26ReYFP reporter mice. Briefly, naive CD4+ T cells were
sorted from Il17aCreR26ReYFP mice, differentiated as above in the
presence of activin-A, and their cytokine profile was examined.
Consistent with previous reports, we found that cell cultures
consisted of eYFP+ Th17 cells expressing IL-17A and eYFP−
Th17 cells, most of which also expressed IL-17A, a finding as-
sociated with PMA/ionomycin-mediated induction of intracel-
lular IL-17 before Cre expression leads to deletion of loxp-
flanked sequences (SI Appendix, Fig. S2C) (10, 27). As expec-
ted, the frequencies of IL-17−IFN-γ+ and IL-17−IL-10+ CD4+
T cells, along with those of IL-17–secreting γδ+ T cells, were
considerably lower to those of Th17 cells, corroborating the
differentiation of Th17 cells (SI Appendix, Fig. S2 C and D) (28).
Similar to the findings mentioned above, activin-A signaling
decreased the percentages of IFN-γ+IL-17+ Th17 cells, consid-
ered pathogenic, and increased the frequencies of nonpathogenic
IL-10+IL-17+ Th17 cells (SI Appendix, Fig. S2C).
We next explored whether activin-A represses the differenti-
ation of pathogenic Th17 cells through activation of its canonical
signaling pathways. Interestingly, treatment with SIS3, a Smad3
inhibitor, or with an ALK4-blocking antibody, reversed activin-
A–driven up-regulation of Il10, Ahr, and Maf, while it restored
expression of Ifng, Tnf, and Csf2 to levels similar to PBS-treated
Th17 cells (SI Appendix, Fig. S2E). Similarly, GM-CSF, TNF-α,
and IFN-γ production was restored in act-A–Th17 cells in the
presence of SIS3, whereas activin-A–induced IL-10 increase was
abolished (SI Appendix, Fig. S2F). Altogether, these findings
identify activin-A as a negative regulator of pathogenic tran-
scriptional programs in Th17 cells.
Activin-A Restrains the Encephalitogenic Potential of Th17 Cells. In
view of the effects of activin-A on the suppression of the path-
ogenic profile of Th17 cells, we postulated that it may restrain
their encephalitogenic functions in vivo. To address this, DLN
cells isolated from C57BL/6 mice primed with CFA/MOG35–55,
were restimulated with MOG35–55 in vitro under Th17-polarizing
conditions and in the presence of activin-A (9, 10, 27). CD4+
T cells were isolated from DLN cultures and adoptively trans-
ferred into Rag-1−/− recipients. Remarkably, evaluation of the
clinical and histopathological disease progression in Rag-1−/−
mice reconstituted with act-A–Th17 cells revealed significantly
reduced clinical scores and dampened inflammatory cell in-
filtration and demyelination in the spinal cords as compared to
recipients of control-treated Th17 cells (Fig. 3 A and B). De-
creased EAE severity was associated with significantly decreased
frequencies of CNS-infiltrating IL-17+, IFN-γ+, GM-CSF+, and
IL-17+IFN-γ+ and IL-17+GM-CSF+ CD4+ T cells, whereas the
percentages of IL-10+ T cells were increased (Fig. 3C). In
agreement, GM-CSF, TNF-α, and IL-17 levels in the CNS were
decreased, concomitant with a more than twofold increase in IL-
10 production (Fig. 3D). Consistent with the CNS findings, ex-
amination of the recall responses of DLN cells to MOG35–55
revealed that T cell proliferation, along with IL-17, GM-CSF, and
IFN-γ release, were diminished in recipients of act-A–Th17 cells
(SI Appendix, Fig. S3A). Collectively, these data demonstrate that
activin-A restrains the encephalitogenic potential of Th17 cells.
CD73 Signaling Is Essential for Activin-A–Mediated Suppression of
Pathogenic Th17 Cell Functions. Interestingly, our whole-genome
profiling studies identified Nt5e as one of the most up-regulated
genes in act-A–Th17 cells (Fig. 2B). Nt5e encodes the plasma
membrane ecto-5′-nucleotidase (CD73) that catalyzes the degrada-
tion of adenosine monophosphate (AMP) to adenosine (29, 30).
Hence, we next investigated the role of CD73 in the suppressive
effects of activin-A on the pathogenic Th17 signature. In line with
our RNA-seq data, we found significantly increased CD73 expression
in Th17 cells differentiated in the presence of activin-A (Fig. 4 A and
B and SI Appendix, Fig. S3B). Notably, CD39 (encoded by Entpd1)
that catalyzes the degradation of extracellular ATP (eATP) into
AMP and provides the substrate for CD73 (29, 30), was also up-
regulated in act-A–Th17 cells (Fig. 4 A and B and SI Appendix, Fig.
S3B). Treatment with SIS3 or anti-ALK4 antibody diminished
activin-A–triggered increase in Nt5e and Entpd1 expression in Th17
cells (SI Appendix, Fig. S3C). Interestingly, intracellular cytokine
staining showed that CD73+CD39+CD4+ T cells, generated upon
0
20
40
60
80
100
0
100
200
300
0
25
50
75
100
0
100
200
300
0
5
10
15
A
EA
E
cli
n
ic
a
ls
co
r e
0
1
2
3
4
**
*
***
***
**
***
p
<
0
.0001
Time (d)
2016128 24 3228
pg
/m
l
CNSD
GM-CSF
*** **
TNF- IL-17
*
IL-10
*

***
H
&E
LF
B
B
act-A-Th17 cells
C57BL/6-Rag1-/- transferred with:
IL-17+ IFN + IL-17+
IFN- +
IL-17 +
GM-CSF+
GM-CSF+

C
***
**
***
CD
4+
T
ce
lls
(%
)
CNS
**
***
IL-10+
**
C57BL/6-Rag1-/-
transferred with:
Th17 cells
act-A-Th17 cells
Th17 cells
Fig. 3. Activin-A suppresses Th17 cell encephalito-
genicity. (A) EAE disease scores of C57BL/6-Rag1−/−
mice reconstituted with CD4+ T cells from CFA/MOG-
immunized mice and restimulated for 3 d with
MOG35–55, IL-23, and activin-A (act-A–Th17 cells) or
PBS (Th17 cells). Regression analysis of the clinical
scores is also shown. Dashed lines indicate the 95%
confidence intervals of the regression lines. Statistical
significance was obtained by two-way ANOVA, fol-
lowed by Bonferroni’s multiple comparisons test (n =
6 mice per group). (B) Representative hematoxylin/
eosin (H&E) staining on spinal cord sections. LFB,
Luxol Fast Blue. (Scale bars, 50 μm.) (C) Cumulative
data showing the percentages of CNS-infiltrating
cytokine-producing CD4+ T cells. Each symbol repre-
sents an individual mouse. Data are mean ± SEM (n =
6 mice per group). (D) Cytokine release in spinal cord
homogenates. Data are mean± SEM of triplicate
wells (n = 6 mice per group). Statistical significance
was obtained by Student’s t test; *P < 0.05, **P <
0.01, and ***P < 0.001. Data displayed represent one
of two independent experiments.
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differentiation of Th17 cells with activin-A, exhibited increased IL-10
production (SI Appendix, Fig. S3D). Consistent with these in vitro
findings, therapeutic administration of activin-A in vivo enhanced
CD73 and CD39 expression by CD4+ T cells in the DLNs of
mice undergoing EAE (SI Appendix, Fig. S3E).
Since activin-A up-regulated the expression of CD73, involved
in the degradation of eATP to adenosine, we investigated the
function of CD73 in act-A–Th17 cells. To address this, we added
exogenous ATP and quantified the residual eATP after 8-h in-
cubation. Indeed, we detected reduced concentrations of eATP
in culture supernatants of Th17 cells stimulated with activin-A,
compared to control-treated Th17 cells (Fig. 4C). Conversely,
treatment with the CD73 inhibitor, AMP-CP, increased eATP
levels, suggesting that CD73 expressed in act-A–Th17 cells
promotes eATP catabolism (Fig. 4C).
Based on the aforementioned findings, and considering the
key role of inflammatory eATP in driving Th17 pathogenicity
(29), we interrogated the effects of CD73 on activin-A–mediated
modulation of the Th17 profile. Inhibition of CD73 signaling
reversed activin-A–induced suppression of Csf2 and Ifng in Th17
cells (Fig. 4D). In contrast, AMP-CP decreased activin-A–mediated
up-regulation of genes associated with nonpathogenic Th17 cells,
such as Il10, Entpd1, Ahr, Maf, Cyp1a1, and Nt5e (Fig. 4D). CD73
blockade also reduced activin-A–mediated IL-10 release and re-
stored GM-CSF and IFN-γ production by Th17 cells (Fig. 4E).
To substantiate these in vitro observations, we examined
whether in vivo blockade of CD73 signaling reverses activin-
A–mediated suppression of Th17 encephalitogenicity. To ad-
dress this, we isolated DLN cells from CFA/MOG35–55-immu-
nized mice and restimulated them in vitro under Th17-polarizing
conditions with MOG35–55 and activin-A (as described in Fig. 3A),
in the presence of a CD73 blocking antibody or Ig control. CD4+
T cells were isolated from DLN cultures and transferred into Rag-
1−/− mice, followed by administration of anti-CD73 or Ig control
(experimental protocol in SI Appendix, Fig. S4A). Recipients of
control-treated Th17 cells, administered with anti-CD73 antibody,
exhibited heightened EAE scores, compared to mice that received
Ig control, consistent with the previously described immunosup-
pressive effects of CD73 on T cell responses (Fig. 5A) (29, 30).
Remarkably, in contrast to mice reconstituted with act-A–Th17
cells and administered Ig, mice treated with anti-CD73 displayed
earlier EAE onset and exacerbated disease severity (Fig. 5A). In
addition, histopathological analyses detected increased immune
cell infiltration and demyelination in the spinal cords in mice
transferred with act-A–Th17 cells upon anti-CD73 administration
(SI Appendix, Fig. S4B). Consistent with the more severe disease
phenotype, increased GM-CSF, IFN-γ, and decreased IL-10 levels
were observed in the spinal cords (Fig. 5B).
To validate and extend the in vivo findings obtained using the
anti-CD73 blocking antibody, we performed experiments on Nt5e−/−
mice. Since previous studies have generated conflicting data,
reporting both attenuation and worsening of EAE in Nt5e-deficient
mice (31–33), we focused our studies on the effects of activin-A on
Nt5e−/− CD4+ T cells. To this end, we generated MOG-reactive
activin-A or control-treated Th17 cells (as above) from CFA/
MOG35–55-immunized Nt5e
+/+ or Nt5e−/− mice and transferred
them into Rag-1−/− recipients. Indeed, Nt5e deficiency in CD4+
T cells interfered with the ability of activin-A to suppress the
encephalitogenicity of Th17 cells, resulting in higher EAE scores in
recipients of act-A–treated Nt5e−/− Th17 cells, as compared to Rag-
1−/− mice reconstituted with their WT counterparts (SI Appendix,
Fig. S4C). Overall, these findings suggest that CD73 signaling is
essential for activin-A–mediated suppression of the pathogenic sig-
nature and the encephalitogenic functions of Th17 cells.
AhR Drives CD73 and Antiinflammatory Gene Expression in Th17 Cells
in Response to Activin-A. We next investigated the transcriptional
mechanisms through which activin-A induces CD73 up-
regulation in Th17 cells. Through analyses of published chromatin
immunoprecipitation sequencing (ChIP-seq) datasets, we identi-
fied enriched ChIP-seq signals for several Th17 cell-associated
TFs, including STAT3, c-Maf, and RORγt in the Nt5e locus,
1,700 bp downstream the transcription start site (TSS) (SI Ap-
pendix, Fig. S5A) (34–37). We also found a significant enrichment
of H3K4me1 and H3K27ac histone modifications surrounding this
site, implying an active chromatin state (SI Appendix, Fig. S5A). In
view of these findings, and considering the role of STAT3 in
driving CD73 expression in T cells (34), we explored the effects of
activin-A on STAT3 activation. Flow cytometry studies revealed
that activin-A increased STAT3 phosphorylation in Th17 cells
(Fig. 6A), while blockade of activin-A canonical signaling path-
ways decreased STAT3 activation (SI Appendix, Fig. S5B). Nota-
bly, ChIP followed by qPCR analyses demonstrated an enhanced
recruitment of STAT3 to its target sequences on the Nt5e and on
the Entpd1 promoters in act-A–Th17 cells (Fig. 6B) (29, 34).
Conversely, inhibition of STAT3 signaling on day 3 following
Th17 cell polarization decreased CD39 and CD73 up-regulation
in act-A–Th17 cells (Fig. 6 C and E). STAT3 inhibition also
reduced activin-A–mediated up-regulation of IL-10 (Fig. 6E).
Activin-A did not decrease the mRNA levels of the CD73
transcriptional repressor, growth factor independent-1 (Gfi-1),
a mechanism utilized by TGF-β to induce CD73 expression in
T cells (SI Appendix, Fig. S5C) (34).
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Given that STAT3 inhibition did not completely abolish activin-
A–induced Nt5e up-regulation in Th17 cells, we explored the roles
of AhR and c-Maf, TFs shown to be up-regulated in act-A–Th17 cells
(Fig. 2E). Indeed, we found increased c-Maf and AhR protein levels
in Th17 cells differentiated in the presence of activin-A (Fig. 7 A and
B). Moreover, confocal microscopy studies detected enhanced AhR
and c-Maf translocation into the nucleus of act-A–Th17 cells (SI
Appendix, Fig. S5D). Bioinformatics analyses revealed two novel
binding sites of AhR and two of c-Maf on theNt5e locus, including the
+1,700-bp site (SI Appendix, Fig. S5E, site 2). Using these genomic
segments, we undertook ChIP assays and observed enriched binding
of AhR and c-Maf to the +1,700-bp site and also to the−3,600-bp site
on the Nt5e promoter in act-A–Th17 cells (Fig. 7C).
Further bioinformatics analyses of the Entpd1 promoter
identified two previously described AhR binding sites, one of
which was in close proximity to a novel c-Maf binding site (SI
Appendix, Fig. S5E). We detected increased binding of AhR on
site 1 and site 2 on the Entpd1 promoter in act-A–Th17 cells,
while no differences were observed in c-Maf binding compared
to PBS-treated Th17 cells (Fig. 7D). Additional data revealed a
marked enrichment of AhR binding to its respective site in the
Il10 promoter (−300 bp), along with c-Maf recruitment to its
MARE-2 site in act-A–Th17 cells (Fig. 7E) (29, 38, 39). As
expected, AhR bound to its respective site on the Cyp1a1 pro-
moter in act-A–Th17 cells (SI Appendix, Fig. S5F) (26).
Notably, through bioinformatics analyses, we identified a re-
gion located in the Il10 conserved noncoding sequence-9 locus, 9
kb upstream the TSS, wherein STAT3 and AhR were predicted
to bind in close proximity. Indeed, through sequential ChIP as-
says we detected a significant enrichment of both AhR and
STAT3 on the Il10 conserved noncoding sequence-9 locus,
previously shown to control Il10 expression (28), in act-A–Th17
cells (Fig. 7F). To further validate these findings, we performed
in silico analysis of putative AhR and STAT3 protein–protein
interactions. Using the crystal structure of the heterodimeric
Hif1-α–ARNT complex with hormone response element DNA as
positive control, we proceeded into molecular docking experi-
ments. Interestingly, the docked structure of the known complex
of Hif1-α–ARNT showed similar binding affinity (ΔG) and dis-
sociation constant (Kd) values (ΔG = −11.6 Kj/mol, Kd = 3.0e-
09) with the docked structure of the AhR-ARNT heterodimer in
complex with the dioxin response element and the unphos-
phorylated mouse STAT3 core fragment (ΔG = −11.3 Kj/mol,
Kd = 4.9e-09). Furthermore, superimpositions of the solved
structures comprising the docked pose of STAT3-AhR-ARNT
showed extremely low RMSD values between the carbon
a-atoms (RMSD < 0.01) (SI Appendix, Fig. S5G). Notably, the
docked structure of STAT3-AhR-ARNT remained constant
throughout the 10-ns molecular dynamics simulation, and when
superimposed with the docking structure before the dynamics
simulation, the RMSD value between the carbon a-atoms was
calculated to be 0.2 Å. These findings suggest that the proposed
docking result of STAT3-AhR-ARNT is highly reliable and ex-
hibits high thermodynamic stability and propose that AhR,
ARNT, and STAT3 form a tripartite molecular complex that
controls Il10 in Th17 cells in response to activin-A.
In view of the aforementioned findings showing the effects of
AhR on controlling Nt5e and Entpd1 expression in act-A–Th17
cells, we hypothesized that inhibition of AhR signaling would
reverse activin-A effects on antiinflammatory gene induction.
Indeed, pharmacological inhibition of AhR reversed activin-
A–driven Nt5e, Il10, Entpd1, and Maf up-regulation in Th17
cells (Fig. 7G). In contrast, treatment with CH-223191 restored
Csf2 and Ifng levels in act-A–Th17 cells (Fig. 7G). As expected,
blockade of AhR signaling abrogated activin-A–induced AhR
activation, as evidenced by abolished Cyp1a1 expression
(Fig. 7G). Similar findings were obtained when IL-10, IFN-γ, and
GM-CSF were quantified in culture supernatants (SI Appendix,
Fig. S5H); AhR blockade also suppressed activin-A–induced
increase in the frequencies of CD73+CD39+CD4+ T cells (SI
Appendix, Fig. S5I). Collectively, these data suggest that AhR
directly controls activin-A–induced up-regulation of Nt5e,
Entpd1, and key antiinflammatory genes in Th17 cells.
Hif1-α Suppression Is Crucial for Activin-A–Mediated Modulation of
the Pathogenic Th17 Cell Signature. Hif1-α signaling plays a pivotal
role in the differentiation of pathogenic Th17 cells (29, 40, 41).
Given that activin-A represses transcriptional programs associated
with Th17 pathogenicity, we hypothesized that activin-A may neg-
atively regulate Hif1-α responses. Interestingly, Th17 cells differ-
entiated in the presence of activin-A exhibited decreased Hif1-α
protein levels (Fig. 8A). In support, confocal microscopy studies
revealed that whereas Hif1-α was localized mainly in the nucleus of
Th17 cells, it mostly accumulated in the cytoplasm of act-A–Th17
cells (SI Appendix, Fig. S6A). Activin-A signaling did not affect
Hif1α gene-expression levels, suggesting that it acts via a post-
transcriptional mechanism (SI Appendix, Fig. S6B).
To assess the functional relevance of the suppression of Hif1-α
expression for the modulation of the pathogenic Th17 cell signature
by activin-A, we conducted Hif1-α overexpression experiments.
For this, we crossed LSL-Hif1dPA mice, which conditionally ex-
press a form of hemagglutinin-tagged human HIF1A cDNA, that
escapes recognition by the von Hippel–Lindau tumor-suppressor
protein by virtue of proline to alanine substitutions, with a Cd4-
Cre mouse strain [Tg(CD4-Cre)1Cwi] (41). In the resulting
progeny (hereafter referred to as Hif-Tg/CD4), excision of a
floxed stop cassette enables the overexpression of Hif1-α in CD4+
T cells. Indeed, we found that CD4+ T cells isolated from Hif-Tg/
CD4 mice and differentiated under Th17-polarizing conditions, in
the presence of activin-A, exhibited enhanced expression of sig-
nature genes associated with Th17 pathogenicity (Fig. 8B). Con-
versely, overexpression of Hif1-α abrogated activin-A–induced up-
regulation of antiinflammatory genes in Th17 cells (Fig. 8B).
Subsequently, we explored the molecular mechanisms through
which activin-A regulates Hif1-α expression in Th17 cells. In
support of the aforementioned qPCR findings, the expression
of the Hif1-α inhibitor (encoded by Hif1an), known to control
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Hif1-α transcriptionally (42), was not altered in act-A–Th17 cells
(SI Appendix, Fig. S6B). Cycloheximide chase assays demon-
strated that, even in the context of disrupted protein translation,
HIF1-α levels remained higher in control-treated Th17 cells as
compared to act-A–Th17 cells (SI Appendix, Fig. S6C), suggesting
that activin-A signaling affects Hif1-α stability in Th17 cells. Previous
studies by our groups have demonstrated that AhR mitigates Hif1-α
stability in Tr1 and Foxp3+ Treg cells through binding to the pro-
moters of Egln1, Egln2, and Egln3 genes (encoding prolyl hydroxy-
lase domain proteins [Phd]2, Phd1, and Phd3, respectively) and
activating Phd-induced Hif1-α degradation (29). In view of the
aforementioned findings, we speculated that activin-A may affect
Hif1-α stability through Egln1, Egln2, or Egln3 induction. Indeed,
we detected significantly increased Egln1 and Egln2 expression in
Th17 cells differentiated in the presence of activin-A (Fig. 8C).
Moreover, ChIP assays revealed a significant enrichment of AhR
binding to its XRE site in the Egln2 promoter in act-A–Th17
cells (Fig. 8D), while inhibition of AhR signaling abrogated
activin-A–induced increase in Egln2 levels (Fig. 8C). Altogether,
these data suggest that AhR activation triggered by activin-A
suppresses pathogenic programs in Th17 cells partly through
Phd1-mediated Hif1-α regulation.
To determine whether Phd1 induction was essential for
activin-A–mediated modulation of the Th17 signature, we iso-
lated naive CD4+ T cells from Egln2−/− mice and differentiated
them toward the Th17 lineage, in the presence or absence of
activin-A. Notably, Egln2 deficiency reversed activin-A–induced
Il10, Cyp1a1, Nt5e, and Entpd1 up-regulation, while it restored
Csf2 and Ifng levels in Th17 cells (SI Appendix, Fig. S6D). Still,
Il17, Ahr, and Maf expression was not affected by Egln2 de-
ficiency, suggesting that other members of the Phd family con-
tribute to activin-A effects (SI Appendix, Fig. S6D).
Activin-A Signaling Alters the Proteomic Profile of Th17 Cells. In an
effort to complement the transcriptomics and qPCR observa-
tions with protein-level evidence, we applied in-depth quantita-
tive proteomics analyses, using a method that employs highly
orthogonal 2D ultrahigh-performance liquid chromatography in
combination with nanospray ultrahigh-resolution tandem mass
spectrometry. Interestingly, 6,488 proteins were quantitatively
profiled across all samples (peptide level q < 0.01), of which 409
were differentially expressed in act-A–Th17 cells (Fig. 8E).
Principal component analysis of differentially expressed proteins
(DEPs) showed that act-A–Th17 cells clustered separately from
control-treated Th17 cells (SI Appendix, Fig. S7A). Selected
DEPs, along with the biological process they participate in, are
depicted in a heatmap format (Fig. 8E). Notably, certain of the
DEPs were also identified in the RNA-seq datasets (Fig. 8E).
GO analysis of the DEPs showed significant enrichment for key
immunological pathways, including positive regulation of cell
migration, negative regulation of T cell receptor signaling, acti-
vation of MAPK activity, methylation, positive regulation of
transcription, and protein phosphorylation (Fig. 8E). IPA ca-
nonical pathway analyses identified a broad spectrum of differ-
entiated cytosolic, membrane-bound, and secreted proteins that
collectively predicted the activation of STAT3 in Th17 cells
differentiated in the presence of activin-A, supporting the
aforementioned mechanistic findings on activin-A–induced
STAT3 activation (P = 4.0 e-3; z-score = 2.0) (Fig. 8F). More-
over, IPA demonstrated a significant enrichment of the T cell
receptor (P = 5.2 e-4) and the NF-κB signaling pathways among
the DEPs in act-A–Th17 cells (P = 1.3e-3).
To decipher the clinical relevance of our in vivo findings, we
isolated human naive CD4+ T cells from RRMS patients (and
healthy controls) and polarized them toward the Th17 cell
lineage, in the presence or absence of activin-A. Similar to our
observations in mouse T cells, activin-A stimulation decreased
the expression of factors associated with pathogenic Th17 cells,
such as, Ifng, Tbx21, and Csf2, while it enhanced Cyp1a1 and
Nt5e expression (Fig. 8G and SI Appendix, Fig. S7A). IFN-γ and
IL-17 protein levels were significantly decreased, while IL-10 was
up-regulated in human Th17 cells differentiated in the presence
of activin-A (Fig. 8H and SI Appendix, Fig. S7B). Subsequently,
we determined whether activin-A signaling can restrain robust
inflammatory responses generated by CD4+ T effector cells in
RRMS patients and healthy donors. Indeed, treatment of anti-
CD3/CD28-activated CD4+ T effectors with activin-A decreased
IFN-γ and IL-17 production, concomitant with increased IL-10
levels (SI Appendix, Fig. S7C). Finally, we analyzed the correla-
tion between serum activin-A and IFN-γ, IL-17, and IL-10 levels
in CD4+ T effectors restimulated ex vivo. A negative correlation
between serum activin-A levels and IFN-γ and IL-17 production
in CD4+ T cells from RRMS patients was observed, while a
positive correlation was identified between higher IL-10 ex-
pression in CD4+ T cells and activin-A release in the serum (SI
Appendix, Fig. S7D). These findings suggest that activin-A sig-
naling also restrains proinflammatory human Th17 cell re-
sponses generated in the context of RRMS.
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resents the mean ± SEM of duplicate wells and corresponds to one of four
independent experiments. (D) Cumulative data showing the percentages of
CD39+, CD73+, and CD39+CD73+ among CD4+ T cells. Data are mean ± SEM;
each symbol corresponds to one of four independent in vitro experiments.
(E) IL-10 in culture supernatants. Each symbol represents the mean ± SEM of
triplicate wells and corresponds to one of four independent experiments.
Statistical analysis was performed by unpaired Student’s t test; *P < 0.05, **P <
0.01 and ***P < 0.001.
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Discussion
Identification of the factors that control the balance between
pathogenic and nonpathogenic Th17 cell states is essential
for exploiting their beneficial host defense functions, while
preventing their detrimental effects that trigger autoimmune
diseases (2, 3). The present study demonstrates that systemic
administration of activin-A ameliorates EAE severity, associated
with decreased activation of Th17 cells. Notably, activin-A
coopts a CD73-dependent molecular pathway that silences
pathogenic gene expression and inhibits encephalitogenic func-
tions of Th17 cells. Concomitantly, activin-A activates AhR,
c-Maf, and STAT3 signaling to boost antiinflammatory gene
programs in Th17 cells. Interestingly, activin-A–induced sup-
pression of Th17 pathogenicity is associated with negative reg-
ulation of Hif1-α, pointing to a link between activin-A signaling
and metabolic regulation in Th17 cells.
Activin-A exerts neuroprotective effects in animal models of
stroke and excitotoxic injury (43, 44). Moreover, oligodendrocyte
differentiation and myelination are impaired in mice with
oligodendrocyte-specific deletion of ALK4, emphasizing potent
CNS-repairing functions for activin-A (45). Activin-A is also up-
regulated in microglia and macrophages with an M2-like pheno-
type, considered to exert tissue-repair functions (46). Still, the ef-
fects of activin-A on encephalitogenic T cell responses and
associated CNS autoimmunity remain unexplored. Here, we dis-
covered that administration of activin-A attenuated EAE and this
was at least partly mediated by inhibition of Th17 effector re-
sponses. This was evidenced by decreased infiltration of pathogenic
IL-17/IFN-γ double-positive CD4+ T cells in the CNS, accompa-
nied by impaired autoantigen-driven recall T cell responses in the
DLNs. In addition, administration of activin-A restrained the in-
filtration of inflammatory myeloid cells in the CNS, concomitant
with a reduction in GM-CSF, IL-1β, and TNF-α, cytokines that
govern myeloid cell recruitment and EAE pathogenesis. Studies by
our group and others have highlighted crucial roles of activin-A in
Th cell differentiation and effector functions (19–23). The present
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findings expand the array of functions of this pleiotropic cytokine
uncovering a crucial role for activin-A in the suppression of Th17
responses and linked CNS autoimmunity.
An intriguing finding of our studies was that activin-A signaling
through its canonical pathways inhibited the differentiation of
Th17 cells with pathogenic properties, as evidenced by repression
of a constellation of genes linked to Th17 pathogenicity, including
Ifng, Csf2, Il1b, Tbx21, and Batf (9–11, 24, 25, 47). In addition,
Th17 cells generated in the presence of activin-A exhibited de-
creased encephalitogenicity, as evidenced by diminished ability to
elicit EAE upon transfer in vivo. Concomitantly, we discovered
that activin-A/ALK4 signaling up-regulated the expression of
antiinflammatory genes associated with nonpathogenic Th17 cells,
such as Il10, Maf, and Ahr (9–11, 24, 25, 29, 47). Seeking to un-
cover the molecular mechanisms involved, we identified the CD73
ectonucleotidase as a critical driver of activin-A–induced sup-
pression of the pathogenic signature and encephalitogenic func-
tions of Th17 cells. Previous studies have demonstrated that CD73
expression in Th17 cells is dependent on IL-6–induced STAT3
activation and TGF-β–mediated inhibition of the transcriptional
repressor, Gfi-1 (34). Here, we demonstrated that activin-A also
engages STAT3-dependent pathways to up-regulate CD73 ex-
pression in Th17 cells; however, its effects were independent of
Gfi-1 or TGF-β signaling. In agreement with our findings, CD73 is
induced in TGF-β receptor-deficient CD4+ T cells (48), suggest-
ing that its expression is also regulated by other factors. Notably,
we detected decreased STAT3 phosphorylation in Th17 cells
upon inhibition of Smad2/3 signaling pathways. In a reciprocal
manner, recent studies have demonstrated that activin-A up-
regulates connective tissue growth factor (CTGF) expression in
endometrial cells through STAT3-induced Smad2/3 phosphory-
lation (49). Altogether, these studies uncovering a link between
Smad2/3 and STAT3 intracellular signaling pathways downstream
of activin-A activation.
Interestingly, through analyses of ChIP-seq datasets we de-
tected enriched binding of Th17 cell-associated TFs, including
STAT3, c-Maf, and RORγt, along with the histone modifications
H3K4me1 and H3K27me1, at a novel site (+1,700 bp) on the
Nt5e gene, highlighting this region as a potentially important
regulatory hub controlling CD73 expression. Indeed, we de-
tected enriched binding of c-Maf to this site in act-A–Th17 cells,
uncovering a previously unidentified role of c-Maf in regulating
Nt5e transcription. We also found that c-Maf controlled IL-10
up-regulation in act-A–Th17 cells through enhanced binding to
the Il10 locus. Together with recent studies demonstrating im-
paired IL-10 expression in Maf −/− Th17 cells, these findings
emphasize the central role of c-Maf in regulating IL-10 expres-
sion in Th17 cells (50). Apart from c-Maf, a striking increase in
AhR levels was detected in Th17 cells differentiated with activin-
A. We also discovered enriched binding of AhR on the Nt5e,
Entpd1, and Il10 loci in act-A–Th17 cells. Interestingly, our
findings demonstrated that STAT3 forms a multipartite tran-
scriptional complex with AhR and ARNT that seems to be im-
portant in activin-A–induced Il10 up-regulation in Th17 cells.
Inhibition of AhR signaling reversed activin-A–induced up-
regulation of Nt5e, Entpd1, Il10, and Maf in Th17 cells, while it
restored Csf2 and Ifng. Considering that AhR drives the differ-
entiation of distinct Th cell subsets, including Foxp3+ Tregs,
Th17, and Tr1 cells in response to divergent cytokines and en-
vironmental cues (8, 26, 29, 38, 39), our findings add activin-A to
the increasing number of factors that integrate AhR signaling to
shape Th responses.
Activin-A coopted CD39 and CD73 functions to reduce in-
flammatory eATP concentrations in Th17 cells. Moreover,
activin-A decreased the protein levels of ATP-induced Hif1-α
in Th17 cells through up-regulation of the Hif1-α inhibitors,
Phd-1 and Phd-2 (29, 40, 41). In fact, we showed that negative
regulation of Hif1-α was essential for activin-A–mediated
suppression of the pathogenic Th17 profile. Altogether,
these findings propose a mechanism wherein activin-A sig-
naling through its canonical pSmad2/3 pathways induces AhR,
STAT3, and c-Maf activation which drive CD39 and CD73 up-
regulation in Th17 cells that, in turn, deplete eATP, dampen
Hif1-α signaling, and restrain Th17 pathogenicity (SI Appendix,
Fig. S8). Notably, our proteomics analyses highlighted the
pleiotropic effects of activin-A on Th17 responses, as evi-
denced by perturbations in T cell receptor and NF-κB signaling
pathways and activation of MAPK activity, phosphorylation,
and histone methylation, molecular pathways that are closely
linked to Th17 cell differentiation and pathogenicity (7,
34, 47).
Of translational relevance, we discovered increased activin-A
levels in the serum and cerebrospinal fluid of RRMS patients.
Considering the enhanced immunosuppressive effects of
activin-A in EAE, increased activin-A expression in the context
of MS may seem counterintuitive. Still, similar findings have
been documented for IL-10 and TGF-β expression in RRMS
patients, supporting the notion that although these immuno-
regulatory factors are increased, their functions and their sig-
naling components may be compromised possibly as a result of
the highly inflammatory tissue milieu (51–53). Moreover, lim-
itations and confounding variables (i.e., medication) often ob-
served when profiling biological fluids from small cohorts of
individuals may also affect our findings and follow-up studies in
larger cohorts should be conducted. Interestingly, activin-A
stimulation restrained the differentiation of human Th17 cells
with pathogenic properties. Concomitantly, activin-A decreased
IFN-γ and IL-17 release and up-regulated IL-10 levels by T ef-
fector cells from RRMS patients and healthy controls. Overall,
these findings support the notion that stimulation of CNS-reactive
Th17 cells from RRMS patients with activin-A may bestow them
with antiinflammatory, tissue-protective properties and follow-up
studies will address this clinically important question.
In conclusion, our findings uncover functions of activin-A in
suppressing mouse and human Th17 pathogenic responses and
controlling CNS autoimmunity. Considering that ongoing clinical
trials are targeting Th17 pathogenicity for the therapy of auto-
immune diseases, our findings open up new opportunities for the
exploitation of activin-A and its signaling pathways as thera-
peutic targets for the management of MS.
Materials and Methods
A detailed description of the materials and methods is provided in SI Ap-
pendix, SI Materials and Methods.
Human Subjects. Human participants signed an informed consent form and
the study protocol was approved by the Scientific Research Ethics Committees
of “G. Gennimatas” General State Hospital of Athens and the Athens
Naval Hospital.
Induction of Active EAE and Scoring. EAE was induced as described previously
(54). Recombinant activin-A (4 μg per mouse per dose; R&D Systems) or PBS
were administrated (intraperitoneally) every 3 d, after EAE onset (days 10
to 12 or when reaching a clinical score >1), until killed. Dose–response
experiments determined the optimal activin-A dose. Mice were killed at
different time points during the course of the disease. At killing, cells were
isolated from cervical and branchial DLNs and spinal cords for further
experimentation. In recall assays, 5 × 104 DLN cells were cultured in 96-well
U-bottom plates and stimulated with 20 μg/mL MOG35–55 peptide. Cells
were pulsed after 72 h of culture with 3[H]-thymidine (1 μCi per well;
Perkin-Elmer) and harvested 12 h later on a filter using a cell harvester
(17, 18).
Mice. Animal handling and procedures were in accordance with a National
Institutes of Health Statement of Compliance (Assurance) with Standards for
Humane Care and Use of Laboratory Animals (#A5736-01 and A38
516 10006), in compliance with the Johns Hopkins Animal Care and Use
Policies, and with the European Union Directive 86/609/EEC on protection of
animals used for experimental purposes.
T Cell Transfer Model of EAE. C57BL/6 mice were immunized with CFA and
MOG35–55 peptide, as described previously (54). DLN cells were harvested
on day 10 after immunization and restimulated ex vivo with 20 μg/mL
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D
ow
nl
oa
de
d 
at
 C
al
ifo
rn
ia
 In
st
itu
te
 o
f T
ec
hn
ol
og
y 
on
 M
ay
 1
5,
 2
02
0 
00.5
1.0
1.5
2.0
2.5
0
1.0
2.0
3.0
4.0
0
0.5
1.0
1.5
2.0
0.0
0.5
1.0
1.5
2.0
G H
E F
0
25
50
75
TBP
**
Th17 act-A-Th17
Hif1-
Th17
act-A-Th17
116 kDa
36 kDa
A

pr
ot
ei
n 
le
ve
ls
(%
 of
 TB
P)
Hif1-
0
100
200
300
400
500B
re
la
tiv
e
ge
ne
ex
pr
es
si
on
Il10 Csf2 Il17 Ahr Cyp1a1 Maf Nt5e Entpd1 Ifng
**
*
**
*
*
**
*
**
***
**
** ***
**
***
**
**
***
Th17
act-A-Th17
act-A-Th17Hif-Tg
0
50
100
150
200
C
Egln1 Egln2 Egln3
**
* **
re
la
tiv
e
ge
ne
ex
pr
es
si
on
D AhR
Egln2
(XRE2)
* Th17
act-A-Th17act-A-Th17
act-A-Th17 +
CH-223191
Th17
fo
ld
en
ric
hm
en
t
(re
lat
ive
 to
 in
pu
t)
n
g/
m
l
IL-17 IFN- IL-10
*****
*
re
la
tiv
e
ge
ne
ex
pr
es
si
on
Th17
act-A-Th17
0
100
200
300
*
*
*
IL1
0
CS
F2IL1
7
AH
R
CY
P1
A1
MA
F
EN
TP
D1
NT
5E
IFN
G
TB
X2
1
RO
RC
*
*
Th17
act-A-Th17
minus log10p-value
% analyzed vs. total proteins in GO term
Ccl20
Ltb4r
Nt5e
Adam19
Dgat1
Smyd3
Endod1
Entpd1
Tgfb3
Ccr5
Rnf149
Ddit4
Foxn3
Selplg
Nedd4l
Nfkbid
Bach1
Mapkbp1
Itgal
Lat
Creb1
Map3k5
Icos
Thy1
Rai1
Klf3
Ctla4
Nfatc2
Map4k4
Map2k3
Rnf40
Ube3c
Atg101
Faah
Ifi35
Rel
Nfkbie
Tbrg1
Zap70
Il1rap
Lrmp
Ifih1
Tnfaip3
Irf6
Il1r2
Il12rb1
Mafk
Nfkbia
Stat4
Lgals7
Il13
Gene Name Proteomics RNAseq
Biological ProcessTh17 act-A-Th17
Fig. 8. Hif1-α suppression is crucial for activin-A–mediated modulation of the pathogenic Th17 cell signature. (A) Representative immunoblots showing Hif1-
α expression. Quantification of relative Hif1-α protein levels are depicted; TATA binding protein (TBP). Data are mean ± SEM; each symbol corresponds to one
of four independent in vitro experiments. (B) Gene expression of act-A–Th17 or Th17 cells from C57BL/6 or Hif1-Tg/CD4 mice was analyzed by qPCR and
normalized to Gapdh. Each symbol represents the mean ± SEM of triplicate wells and corresponds to one of three independent in vitro experiments. (C) Act-
A–Th17 or Th17 cells were differentiated in the presence of CH-223191 or DMSO. Gene expression was analyzed by qPCR and normalized to Gapdh and
Polr2a. Each symbol is the mean ± SEM of duplicate wells and corresponds to one of four independent in vitro experiments. (D) ChIP analysis demonstrates the
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Heatmap of DEPs in act-A–Th17 cells vs. Th17 cells, along with the biological processes they participate. The proteomics dataset was aligned with the RNA-seq
dataset and a subset of the DEPs was verified to exhibit differential expression at the mRNA level. (F) GO analysis of DEPs in act-A–Th17 cells. (G) Naive CD4+
T cells from RRMS patients were polarized toward the Th17 cell lineage, as indicated. Gene expression was analyzed by qPCR and normalized to B2M. Data are
mean ± SEM of duplicate wells; each symbol depicts an individual donor (n = 7 donors). (H) Cytokine release in culture supernatants. Each symbol represents
the mean ± SEM of triplicate wells and corresponds to an individual donor (n = 12 donors). Statistical analysis was performed by unpaired Student’s t test and
Wilcoxon matched-pairs signed rank test; *P < 0.05, **P < 0.01 and ***P < 0.001.
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MOG35–55 peptide, IL-23 (20 ng/mL; R&D Systems) (Th17 conditions) in the
presence of PBS or activin-A (100 ng/mL), for 72 h. CD4+ T cells were isolated
and adoptively transferred (3 × 106 per mouse) intraperitoneally to C57BL/6-
Rag1−/− naive recipients and 48 h later, pertussis toxin (PTX) was adminis-
tered as above. Mice were monitored clinically at least until day 30. In an-
other set of experiments, Th17 or act-A–Th17 cells (3 × 106), generated as
above, were treated with anti-CD73 blocking antibody (BioXCell; 20 μg/mL)
or IgG control, and then adoptively transferred to C57BL/6-Rag1−/−mice (day
0) as above. C57BL/6-Rag1−/− mice were administered (intraperitoneally)
with anti-CD73 (50 μg per mouse) or IgG control on days 4, 7, 10, and 14
after T cell transfer. In other experiments, Th17 or act-A–Th17 cells (3 × 106)
were generated as above from CFA/MOG-immunized Nt5e−/− or Nt5e+/+ and
transferred into C57BL/6-Rag1−/− mice (day 0).
In Vitro Mouse T Cell Differentiation. CD4+CD62L+ naive T cells were isolated
by magnetic beads (Miltenyi Biotec) or sorted on a BD FACSAria II sorter
from the spleens and lymph nodes of C57BL/6, Hif1-Tg/CD4 I17aCre/R26ReYFP
or Egln2−/− mice and activated with plate-bound anti-CD3 (eBioscience;
1 μg/mL) and soluble anti-CD28 (eBioscience; 1 μg/mL) in 96-well plates, for 3
to 4 d. For Th17 cell differentiation, 105 naive T cells were supplemented
with recombinant IL-6 (Peprotech; 20 ng/mL), IL-1β (Peprotech; 20 ng/mL),
and IL-23 (R&D Systems; 20 ng/mL) in the presence of PBS (control) or activin-
A (100 ng/mL) (9). Dose–response experiments determined the optimal
concentrations of anti-CD3/anti-CD28 antibodies and activin-A. In some ex-
periments, the AhR antagonist (CH-223191, 5 μM; Sigma-Aldrich), the CD73
antagonist (AMP-CP, 100 μM; Sigma-Aldrich), the Smad3 inhibitor (SIS3,
20 μm; Sigma-Aldrich), the neutralizing anti-ALK4 antibody (10 μg/mL; R&D),
the STAT3 inhibitor (STA-21, 10 μM; Cayman Chemical) or vector (PBS) were
administered in T cell cultures, as indicated. Cells were harvested on days 3
to 4 postdifferentiation for RNA extraction and on days 3 to 9 for extra-
cellular or intracellular flow-cytometry staining and cytokine analyses in
culture supernatants.
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